Keywords: GlaxoSmithKline, Theravance, Relovair, COPD, Asthma

Positive Ph III results for GSK and Theravance Relovair in COPD

Article | 03 June 2011

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) and development partner Theravance (Nasdaq: THRX) of the USA have released positive results of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in